Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Transplantation. 2002 Oct 27;74(8):1190-2.

Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases.

Author information

  • 1Department of Pharmacy, Besançon University Hospital, Boulevard Fleming, 25030 Besançon Cedex, France.

Abstract

BACKGROUND:

Hemorrhagic cystitis (HC) is an important cause of morbidity in patients undergoing allogeneic stem-cell transplantation (SCT). Various causes have been identified, such as the use of high-dose cyclophosphamide or busulfan and the occurrence of acute graft-versus-host disease or viral infections (cytomegalovirus, adenovirus, polyomavirus).

METHODS:

The clinical course of four patients treated with factor XIII (FXIII) concentrate for severe HC after allogeneic SCT is described.

RESULTS:

Four patients were treated with one or two infusions of 50 IU/kg of FXIII concentrate. Only one patient showed a plasmatic FXIII decrease before treatment. Three of the four patients responded to this treatment, and HC completely resolved in two of them. No adverse event was observed.

CONCLUSION:

The use of FXIII concentrate can improve the major symptoms of HC in patients with decreased or normal FXIII plasma level after allogeneic SCT.

PMID:
12438970
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk